As of 2026-04-05, the EV/EBITDA ratio of Hainan Huluwa Pharmaceutical Group Co Ltd (605199.SS) is -12.17. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 605199.SS's latest enterprise value is 3,913.94 mil CNY. 605199.SS's TTM EBITDA according to its financial statements is -321.60 mil CNY. Dividing these 2 quantities gives us the above 605199.SS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 16.4x - 18.8x | 17.2x |
| Forward P/E multiples | 9.2x - 11.9x | 10.4x |
| Fair Price | (16.21) - 1.41 | (8.00) |
| Upside | -339.4% - -79.2% | -218.2% |
| Date | EV/EBITDA |
| 2026-03-20 | -11.76 |
| 2026-03-19 | -12.00 |
| 2026-03-18 | -12.16 |
| 2026-03-17 | -12.17 |
| 2026-03-16 | -12.24 |
| 2026-03-13 | -12.23 |
| 2026-03-12 | -12.36 |
| 2026-03-11 | -12.53 |
| 2026-03-10 | -12.54 |
| 2026-03-09 | -12.39 |
| 2026-03-06 | -12.52 |
| 2026-03-05 | -12.24 |
| 2026-03-04 | -12.23 |
| 2026-03-03 | -12.41 |
| 2026-03-02 | -12.29 |
| 2026-02-27 | -12.59 |
| 2026-02-26 | -12.58 |
| 2026-02-25 | -12.47 |
| 2026-02-24 | -12.23 |
| 2026-02-13 | -12.10 |
| 2026-02-12 | -12.15 |
| 2026-02-11 | -12.33 |
| 2026-02-10 | -12.17 |
| 2026-02-09 | -12.24 |
| 2026-02-06 | -12.15 |
| 2026-02-05 | -12.13 |
| 2026-02-04 | -12.21 |
| 2026-02-03 | -12.01 |
| 2026-02-02 | -11.98 |
| 2026-01-30 | -12.06 |
| 2026-01-29 | -12.10 |
| 2026-01-28 | -12.24 |
| 2026-01-27 | -12.38 |
| 2026-01-26 | -12.52 |
| 2026-01-23 | -12.63 |
| 2026-01-22 | -12.56 |
| 2026-01-21 | -12.32 |
| 2026-01-20 | -12.47 |
| 2026-01-19 | -12.38 |
| 2026-01-16 | -12.33 |
| 2026-01-15 | -12.69 |
| 2026-01-14 | -12.95 |
| 2026-01-13 | -13.00 |
| 2026-01-12 | -13.02 |
| 2026-01-09 | -13.15 |
| 2026-01-08 | -13.20 |
| 2026-01-07 | -13.12 |
| 2026-01-06 | -13.33 |
| 2026-01-05 | -13.23 |
| 2025-12-31 | -13.23 |